Small interfering RNA targeting 14-3-3ζ increases efficacy of chemotherapeutic agents in head and neck cancer cells

Molecular Cancer Therapeutics

Volumn 9, Issue 10, 2010, Pages 2676-2688

  Matta, Ajay ^a   DeSouza, Leroi V ^a   Ralhan, Ranju ^a,b,c,d   Siu, K W Michael ^a  

^a YORK UNIVERSITY   (Canada)

^b Joseph and Mildred Sonshine Family Centre for Head and Neck Diseases   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; PACLITAXEL; PROTEIN 14 3 3; PROTEIN 14 3 3ZETA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; CELL GROWTH; CONCENTRATION RESPONSE; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

14-3-3 PROTEINS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL PROLIFERATION; FLOW CYTOMETRY; GENE SILENCING; HEAD AND NECK NEOPLASMS; IN SITU NICK-END LABELING; PROGNOSIS; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 77958049704     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0312     Document Type: Article

References (46)

1. Scully C, Bagan JV. Recent advances in Oral Oncology 2007: imaging, treatment and treatment outcomes. Oral Oncol 2008;44:211-5.
2. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008;371:1695-709.
3. Pignon JP, le Maître A, Bourhis J, MACH-NC Collaborative Group. Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys 2007;69:12-4.
4. Gibson MK, Li Y, Murphy B, et al, Eastern Cooperative Oncology Group. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:3562-7.
5. Budach W, Hehr T, Budach V, Belka C, Dietz K. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 2006;6:28.
6. Harari PM, Wheeler DL, Grandis JR. Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond. Semin Radiat Oncol 2009;19:63-8.
7. Le Tourneau C, Siu LL. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck. Curr Opin Oncol 2008;20:256-63.
8. Matta A, Ralhan R. Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma. Head Neck Oncol 2009;1:6.
9. Ralhan R, Desouza LV, Matta A, et al. iTRAQ-multidimensional liquid chromatography and tandem mass spectrometry-based identification of potential biomarkers of oral epithelial dysplasia and novel networks between inflammation and premalignancy. J Proteome Res 2009;8:300-9.
10. Ralhan R, Desouza LV, Matta A, et al. Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol Cell Proteomics 2008;7:1162-73.
11. Matta A, DeSouza LV, Shukla NK, Gupta SD, Ralhan R, Siu KWM. Prognostic significance of head-and-neck cancer biomarkers previously discovered and identified using iTRAQ-labeling and multidimensional liquid chromatography- tandem mass spectrometry. J Proteome Res 2008;7:2078-87.
12. Arora S, Matta A, Shukla NK, Deo SV, Ralhan R. Identification of differentially expressed genes in oral squamous cell carcinoma. Mol Carcinog 2005;42:97-108.
13. Matta A, Bahadur S, Duggal R, Gupta SD, Ralhan R. Over-expression of 14-3-3ζ is an early event in oral cancer. BMC Cancer 2007;7:169.
14. Lin M, Morrison CD, Jones S, Mohamed N, Bacher J, Plass C. Copy number gain and oncogenic activity of YWHAZ/14-3-3ζ in head and neck squamous cell carcinoma. Int J Cancer 2009;125:603-11.
15. Bajpai U, Sharma R, Kausar T, Dattagupta S, Chattopadhayay TK, Ralhan R. Clinical significance of 14-3-3ζ in human esophageal cancer. Int J Biol Markers 2008;23:231-7.
16. Fan T, Li R, Todd NW, et al. Up-regulation of 14-3-3ζ in lung cancer and its implication as prognostic and therapeutic target. Cancer Res 2007;67:7901-6.
17. Meehan KL, Sadar MD. Quantitative profiling of LNCaP prostate cancer cells using isotope-coded affinity tags and mass spectrometry. Proteomics 2004;4:1116-34.
18. Shen J, Person MD, Zhu J, Abbruzzese JL, Li D. Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res 2004;64:9018-26.
19. Neal CL, Yao J, Yang W, et al. 14-3-3ζ overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Res 2009;69:3425-32.
20. Ghadimi BM, Grade M, Liersch T, et al. Gain of chromosome 8q23-24 is a predictive marker for lymph node positivity in colorectal cancer. Clin Cancer Res 2003;9:1808-14.
21. Tada K, Oka M, Tangoku A, Hayashi H, Oga A, Sasaki K. Gains of 8q23-qter and 20q and loss of 11q22-qter in esophageal squamous cell carcinoma associated with lymph node metastasis. Cancer 2000;88:268-73.
22. Obsilová V, Silhan J, Boura E, Teisinger J, Obsil T. 14-3-3 proteins: a family of versatile molecular regulators. Physiol Res 2008;57:S11-21.
23. Dougherty MK, Morrison DK. Unlocking the code of 14-3-3. J Cell Sci 2004;117:1875-84.
24. Morrison DK. The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol 2009;19:16-23.
25. Lu J, Guo H, Treekitkarnmongkol W, Li P, Zhang J, et al. 14-3-3ζ cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell 2009;16:195-207.
26. Zannis-Hadjopoulos M, Yahyaoui W, Callejo M. 14-3-3 cruciform-binding proteins as regulators of eukaryotic DNA replication. Trends Biochem Sci 2008;33:44-50.
27. Porter GW, Khuri FR, Fu H. Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathways. Semin Cancer Biol 2006;16:193-202.
28. Tzivion G, Gupta VS, Kaplun L, Balan V. 14-3-3 proteins as potential oncogenes. Semin Cancer Biol 2006;16:203-13.
29. Matta A, Tripathi SC, DeSouza LV, et al. Heterogeneous ribonucleoprotein K is a marker of oral leukoplakia and correlates with poor prognosis of squamous cell carcinoma. Int J Cancer 2009;125:1398-406.
30. Sharma C, Kaur J, Shishodia S, Aggarwal BB, Ralhan R. Curcumin down regulates smokeless tobacco-induced NF-κB activation and COX-2 expression in human oral premalignant and cancer cells. Toxicology 2006;228:1-15.
31. Kawamoto S, Iemura N, Inoue Y, Katakura Y, Shirahata S. Effect of 14-3-3 protein induction on cell proliferation of A549 human lung adenocarcinoma. Cytotechnology 2000;33:253-7.
32. Li Z, Zhao J, Du Y, et al. Down-regulation of 14-3-3ζ suppresses anchorage-independent growth of lung cancer cells through anoikis activation. Proc Natl Acad Sci U S A 2008;105:162-7.
33. Niemantsverdriet M, Wagner K, Visser M, Backendorf C. Cellular functions of 14-3-3ζ in apoptosis and cell adhesion emphasize its oncogenic character. Oncogene 2008;27:315-9.
34. Maxwell SA, Li Z, Jaya D, Ballard S, Ferrell J, Fu H. 14-3-3ζ mediates resistance of diffuse large B cell lymphoma to an anthracycline-based chemotherapeutic regimen. J Biol Chem 2009;284:22379-89.
35. Chatterjee D, Goldman M, Braastad CD, et al. Reduction of 9-nitrocamptothecin-triggered apoptosis in DU-145 human prostate cancer cells by ectopic expression of 14-3-3ζ. Int J Oncol 2004;25:503-9.
36. Qi W, Martinez JD. Reduction of 14-3-3 proteins correlates with increased sensitivity to killing of human lung cancer cells by ionizing radiation. Radiat Res 2003;160:217-23.
37. Ahmed KM, Fan M, Nantajit D, Cao N, Li JJ. Cyclin D1 in low-dose radiation-induced adaptive resistance. Oncogene 2008;27:6738-48.
38. Dong S, Kang S, Lonial S, Khoury HJ, Viallet J, Chen J. Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070. Leukemia 2008;22:572-7.
39. Masters SC, Fu H. 14-3-3 proteins mediate an essential anti-apoptotic signal. J Biol Chem 2001;276:45193-200.
40. Cao W, Yang X, Zhou J, Teng Z, Cao L, Zhang X, Fei Z. Targeting 14-3-3 protein, difopein induces apoptosis of human glioma cells and suppresses tumor growth in mice. Apoptosis 2010;15:230-41.
41. Masters SC, Subramanian RR, Truong A, et al. Survival-promoting functions of 14-3-3 proteins. Biochem Soc Trans 2002;30:360-5.
42. Silhan J, Vacha P, Strnadova P, et al. 14-3-3 protein masks the DNA binding interface of forkhead transcription factor FOXO4. J Biol Chem 2009;284:19349-60.
43. Rena G, Prescott AR, Guo S, Cohen P, Unterman TG. Roles of the forkhead in rhabdomyosarcoma (FKHR) phosphorylation sites in regulating 14-3-3 binding, transactivation and nuclear targeting. Biochem J 2001;354:605-12.
44. Subramanian RR, Zhang H, Wang H, Ichijo H, Miyashita T, Fu H. Interaction of apoptosis signal-regulating kinase 1 with isoforms of 14-3-3 proteins. Exp Cell Res 2004;294:581-91.
45. Basu S, Totty NF, Irwin MS, Sudol M, Downward J. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell 2003;11:11-23.
46. Wingate AD, Campbell DG, Peggie M, Arthur JS. Nur77 is phosphorylated in cells by RSK in response to mitogenic stimulation. Biochem J 2006;393:715-24.